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Abstract
In a population-based cohort of Alaska Native persons with chronic HBV infection who were 
HBeAg-negative, we aimed to determine the prevalence of immune active HBV infection over 
time and to determine the relationship between demographic and viral factors on severity of 
disease on liver biopsy. We examined 777 patients infected with five HBV genotypes (A2, B6, 
C2, D2/3, F1). Alanine aminotransferase (ALT) measurements were assessed every 6 months 
during an 8-year period. HBV DNA levels were performed at baseline in 2001 and whenever ALT 
levels exceeded the upper limit of normal (ULN). Immune active chronic HBV infection was 
defined as an ALT >30 U/L men, >20 U/ml women and HBV DNA >2,000 IU/ml during one or 
more times from 2001 and 2008. Liver biopsies were scored using the modified hepatic activity 
index score (HAI) of Knodell and the Ishak fibrosis score. A total of 201 (26%) patients met the 
criteria for immune active HBV. HBV genotype D was less likely to be associated with immune 
active hepatitis than the other 4 genotypes. Of the 46 patients with liver biopsy results, none of the 
15 patients with ALT always below twice the ULN and only 2/19 of those with HBV DNA 
between 2,000 and 20,000 IU/ml had moderate or severe hepatitis, or moderate or severe fibrosis. 
In contrast, 18(58%) of 31 with ALT ≥ twice ULN, and 16 (62%) of 26 with one or more HBV 
DNA levels > 20,000 IU/ml had moderate to severe fibrosis scores (p<0.001).
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Conclusion—Of participants, 26% met criteria for immune active HBV. An HBV DNA level of 
> 20,000 IU/ml was strongly correlated with persons meeting the current guidelines for antiviral 
therapy.
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Chronic infection due to hepatitis B virus (HBV) (1) is a major cause of cirrhosis and 
hepatocellular carcinoma (HCC) worldwide. (2) Persons chronically infected with HBV 
experience four clinical phases of liver disease.(3) Persons that are hepatitis B “e” antigen 
(HBeAg) positive and have detectable viral load can be divided into two groups: those in the 
“immune tolerant phase” who have normal alanine aminotransferase (ALT) levels), and 
those in the “immune active phase” who have elevated ALT levels and active liver disease 
on biopsy.(4) Eventually, most persons will lose HBeAg and develop antibody to HBeAg 
(anti-HBe). The majority of these patients will enter the inactive carrier phase and have 
normal ALT levels, absent or low levels of HBV DNA and quiescent liver disease. 
Nevertheless, it is estimated that 20% to 40% either continue to have active liver 
inflammation and progressive fibrosis or revert from the inactive phase back to the immune 
active phase. However, the proportion of patients over time who will lose HBeAg and have 
active liver disease is not known, as there are few population-based prospective cohort 
studies that examine this question. Furthermore, factors that predict active vs. inactive HBV 
liver disease such as HBV genotype, levels of HBV DNA over time associated with disease, 
age and sex have not been well established.
For over 20 years, the Alaska Native Tribal Health Consortium Liver Disease and Hepatitis 
program has been conducting a large population-based cohort study of chronic HBV 
infection in Alaska. In the 1970s, Alaska Native people were found to have the highest rates 
of HBV infection and HCC of any U.S. born population.(5) Chronic HBV infection 
occurred in Alaska Native persons primarily through acquisition of HBV either at birth or in 
early childhood, as is seen in much of the developing world.(6) In the 1980s, 52,000 Alaska 
Native persons (approximately 75% of the overall population and >90% in the endemic 
geographic areas) were screened for HBV seromarkers, and approximately 40,000 persons 
negative for HBV seromarkers received Hepatitis B vaccine. Universal newborn hepatitis B 
immunization was also introduced at that time, and transmission of HBV in the population 
has almost ceased.(6) This public health program identified 1,536 persons with chronic 
HBV. In 2001, we began testing these patients for HBV DNA and continued to test for other 
HBV seromarkers and aminotransferase levels every 6 months. Herein we describe the 
prevalence of immune active liver disease in a cohort of 777 patients who were HBeAg-
negative in 2001 and were followed through 2008. We examined the demographic and 
laboratory risk factors associated with the immune active phase, as well as the factors 
associated with the presence of moderate to severe liver disease. We also examined the 
levels of hepatitis B surface antigen (HBsAg) in persons who met the criteria for immune 
active hepatitis B to look for any correlations between level HBsAg and severity of liver 
inflammation and fibrosis at the time of biopsy.
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Of the 1,536 Alaska Native persons chronically infected with HBV, defined as HBsAg-
positive on two or more occasions at least 6 months apart, 1,271 persons consented to 
participate in this study. All Alaska Native persons, both consented and not consented, who 
are chronically infected with HBV have been contacted twice each year since 1982 and 
reminded to go to their village clinic or local hospital for a routine blood draw and follow-up 
testing. Seventy percent of Alaska Native persons with chronic HBV infection live in remote 
communities, most not connected by the road system. Blood specimens are centrifuged in 
the village and/or regional clinics and sent to the central laboratory at the Alaska Native 
Medical Center for testing. The results are reviewed weekly by a staff hepatologist and 
project nurse, who make decisions regarding further management, including laboratory tests 
that can be drawn in the village, and need for referral for radiographic studies and/or liver 
biopsy.
This study was approved by the Alaska Area Institutional Review Board and the Centers for 
Disease Control and Prevention Institutional Review Board. In addition, the study was 
cleared by three Alaska Native Health boards: the Alaska Native Tribal Health Consortium 
Health Research Review Committee, the Southcentral Foundation Research Oversight 
Committee, and the Yukon-Kuskokwim Health Corporation. All participants provided 
informed consent.
We follow the Practice Guidelines for Chronic Hepatitis B developed by the American 
Association for the Study of Liver Disease (AASLD) to make decisions regarding antiviral 
therapy and management. In general, all persons had baseline HBV DNA levels on the first 
specimen obtained after 2001 when HBV DNA testing became available in Alaska (Figure 
1).(7) Those persons who were consented also had HBV genotype and sub-genotype testing 
performed. Persons who had a family history of HCC or had an HBV DNA level of over 
2,000 IU/ml on first testing were followed with serial HBV DNA testing every 6 months. In 
addition, HBV DNA testing was repeated on all others who had elevated ALT or aspartate 
aminotransferase (AST) levels. Thus, only those with an HBV DNA level of < 2,000 IU/ml 
on initial testing who had persistently normal ALT/AS T levels did not have repeat HBV 
DNA testing performed. For the purpose of this study, we restricted the cohort to those 
persons who were HBeAg-negative on the first sera drawn after January 2001. The 
following criteria were established by our group in 2001 for recommending a liver biopsy 
based on AASLD Guidelines and as feasible in our population of Alaska Native persons: 1) 
persons with elevated ALT or AST level and HBV DNA > 20,000 IU/ml on any occasion; 
2) persons with elevated ALT or AST > 30 who have HBV DNA between 2,000 and 20,000 
IU/ml on two or more occasions, 3) persons over 40 years of age who previously had an 
HBV DNA between 2,000 and 20,000. We also recommend that persons with a personal 
history of previously treated HCC or family history of HCC with HBV DNA levels of > 
2,000 IU/ml be considered for liver biopsy and evaluated for antiviral therapy.
Liver biopsies were scored using the modified histology activity index score (HAI) of 
Knodell (8) and the Ishak (9) fibrosis score. Patients with moderate or severe hepatitis (HAI 
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≥ 9) and moderate or severe fibrosis (Ishak ≥ 2) who met current AASLD criteria for 
antiviral treatment were compared for factors predicting degree of liver involvement.
For the purposes of this analysis we used a level of ALT of 20 U/L or higher for women and 
≥30 U/L for men as the upper limit of normal. An HBV DNA level > 2,000 IU was 
considered suggestive of immune active hepatitis B. A participant met the study’s criteria 
for immune active hepatitis B if they had an ALT above the defined upper limit of normal 
and an HBV DNA > 2,000 IU/ml, as per NIH criteria, at any time during the study period 
from October 1, 2001 to December 31, 2008.(10)
Laboratory Testing
Serologic testing for HBsAg, anti-HBs and antibody to hepatitis B core antigen (anti-HBc) 
was performed using enzyme-linked immunoassay (Abbott Laboratories, Irving, Texas) at 
the Alaska Native Medical Center clinical laboratory by commercial assay. Between 2001 
and 2006, HBeAg determinations were performed using the One-Step Hepatitis B ‘e’ 
Antigen Test Strip, and the anti-HBe status of each specimen was determined using the 
Maxi: Test Anti-HBe Rapid Test (IND Diagnostic Inc., Delta, BC, Canada) as per the 
manufacturer. Both these tests were validated using sera previously tested with the Abbott 
Laboratories enzyme-linked immunoassay kits. After 2006 HBeAg and anti-HBe were 
performed by ELISA.
HBV viral load determination
Routine HBV viral load measurements conducted from 2001 and 2008 were determined 
using a Real-Time Quantitative polymerase chain reaction (PCR) assay with a lower limit of 
detection of approximately 10,000 copies/ml (200 IU/ml). Briefly, HBV DNA was extracted 
from stored serum specimens using the MagNA Pure Compact System and Total Nucleic 
Acid Extraction kit as per the manufacturer (Roche Diagnostics, Indianapolis, IN). 
Subsequently, a 118-bp fragment of the core gene was amplified and HBV viral loads were 
determined by comparison to a set of HBV DNA standards amplified in parallel with the 
samples being tested.(11) After 2008, HBV viral load measurements were also determined 
by Real-Time Quantitative PCR assay using the Roche Diagnostics COBAS® Ampliprep/
COBAS® Taqman system (Roche Diagnostics, Indianapolis, IN) with a lower limit of 
detection of approximately 100 copies/mL (20 IU/mL). DNA extraction, nested PCR, DNA 
sequencing and genotyping were performed as previously described. (12)
HBsAg Levels
HBsAg levels were determined on sera obtained at the time of liver biopsy using the 
ADVIA (Siemens Diagnostics) testing platform at Beth Israel Deaconess Medical Center at 
Harvard Medical School, Boston Massachusetts. HBsAg levels were analyzed by level of < 
1,000 or ≥ 1,000 IU/ml and by mean geometric titer (GMT).
Statistical Analysis
Comparisons of proportions were made using chi-square, Fisher’s exact, or randomization 
tests as appropriate. Logistic regression analysis was used for adjusted comparisons. Mean 
HAI and Ishak scores were compared using t-tests. Deaths were considered liver related if 
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they had the following ICD10 codes: K701-753, K758-769, B150/9, B159-162, B169-172, 
B178, B188-190, B942, C220-4, C227, or C229. All p-values are two-sided. P<0.05 was 
considered statistically significant.
Results
Prevalence of Immune Active Chronic Hepatitis B Infection
A total of 777 participants with chronic HBV infection were negative for HBeAg on their 
first serologic testing after October 1, 2001. The mean age of the cohort at the start of the 
follow-up was 38.6 years and 420 (54.1%) were male. No patients were documented to be 
positive for antibody to human immunodeficiency virus (HIV) and only two were positive 
for hepatitis C antibody and HCV RNA. During the study period, 201 (25.9%) persons met 
the criteria for immune active chronic hepatitis B and were included in this analysis. The 
characteristics of those who did and did not meet the criteria for immune active hepatitis B 
HBV are displayed in Table 1). HBV genotype was determined for 708 (91%) of the 
participants. Five HBV genotypes have previously been identified in this population, 
genotypes A1, B6, C, D, and F1.(12, 13) Compared to the other four genotypes, persons 
infected with genotype D had significantly lower prevalence of immune active chronic 
hepatitis B (p=0.007). Men were more likely than women to have immune active HBV 
infection (p=0.018). This difference remained after adjustment for HBV genotype (p=0.024) 
[Table 2]. The association of gender and active status was similar across genotypes; no 
significant differences among genotypes were observed (p=0.924).
No difference was found in the proportion of persons aged ≥40 years compared with those 
<40 years who had immune active hepatitis during the study period (25% vs. 27%; p=0.62). 
Interestingly, persons with a BMI ≥30 were significantly less likely than persons with a BMI 
<30 to have immune active hepatitis (23% vs. 30%; p=0.037). However, men were found to 
have higher BMI than women and after adjusting for gender, the relationship between higher 
BMI and lower prevalence of immune active HBV was no longer significant (p=0.09). Also 
no differences in the mortality rate among those with and without immune active disease 
were found during the study interval (p=0.810). Using a logistic model for immune active 
HBeAg-negative hepatitis, only male gender was associated with increased risk (p=0.023), 
and HBV genotype D was associated with a reduced risk (p=0.006) for immune active HBV. 
We also examined the relationship between BMI and HBV Genotype in Table 3. Adjusting 
for gender, the overall test for trend was not statistically significant for decreasing immune 
active HBeAg-negative hepatitis with increasing BMI (p=0.089).
We next examined the maximum ALT level that occurred during the seven years of 
prospective follow-up (Table 4). Males had significantly more abnormal ALT levels than 
females, both in terms of ALT above the normal limit defined (p=0.018) and by the 
proportion of ALT levels above 10 times the upper limit of normal (ULN) (p=0.040). 
However, no differences were found across HBV genotypes for maximum ALT level 
(P=0.76), levels greater than twice ULN (P=0.136) or maximum levels greater than 10 times 
ULN (P=0.538).
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Liver Biopsy in Patients with Immune Active Chronic Hepatitis B Infection
Percutaneous liver biopsy was obtained in 46 (23%) of the 201 participants who met the 
study criteria for immune active hepatitis. Liver biopsy was performed significantly more 
often in patients with ALT greater than twice the ULN compared with those with ALT 
levels between one and two times the ULN (p=0.028) and more frequently in those who had 
one or more HBV DNA values that exceeded 20,000 IU/ml than in those with HBV DNA 
<20,000 IU/ml (p<0.001). There were no differences in the proportion of persons 
undergoing biopsy by age, gender, or BMI. However, a significantly higher proportion of 
persons infected with HBV genotypes C (47%) and F (35%) underwent liver biopsy than 
those with A1 (7%), B6 (17%), or D (18%) (p=0.005; 5 way comparison).
Factors predictive of moderate or severe liver inflammation (HAI≥9) or fibrosis (Ishak ≥2) 
among those who had liver biopsy are shown in Table 5 and Figure 1. We found no 
statistical differences in age, sex or HBV genotype. However, we did find significant 
differences among persons with ALT > vs. < twice ULN (p=0.001) and in those with HBV 
DNA levels > 20,000 vs. those between 2,000 and 20,000 IU/ml (p=0.001) [Table 5]. The 
proportion of persons with Ishak score ≥ 2 was significantly higher, 62% (16/26), for those 
with at least one HBV DNA level that exceeded 20,000 IU/ml compared to only 11% (2/19) 
for those whose levels were above 2,000 but never exceeded 20,000 IU/ml (p<0.001). 
Furthermore, of those in the immune active phase who had at least one ALT level > twice 
the ULN, 58% (18/31) had Ishak fibrosis score of ≥ 2 vs. 0% (0 of 14) whose ALT levels 
never exceeded twice the ULN (p=0.001). For persons with abnormal ALT levels less than 
twice the ULN, the mean HAI score was 1.7 vs. 5.7 for those with ALT levels ≥ twice the 
ULN (p<0.001); the mean Ishak scores were 0.14 vs. 2.0 for those, whose ALT was less 
than twice the ULN compared to those with one or more levels ≥ twice the ULN 
respectively (p<0.001). The mean HAI score for those whose HBV DNA was above 2,000 
IU/mL but never reached 20,000 IU/ml was 3.1 and 5.5 for those who reached 20,000 IU/ml 
or higher during the study period (p=0.023) and the mean Ishak score was 0.53 vs. 2.1 
respectively (p=0.001).
Thirteen of the 777 patients who began the study period as HBeAg-negative had one or 
more reversions to HBeAg-positive. Reversions were more frequently seen in persons 
infected with HBV genotype C compared to the other four genotypes (p=0.003), those with 
at least one HBV DNA level of >20,000 IU/ml (p=0.003) and those with at least one ALT > 
twice the ULN (p=0.023). No differences were seen in the frequency of reversions by age, 
sex, or BMI.
During the study period, 65 of the 777 persons died. Of those in the immune active phase, 
16 (8.7%) of 201 died, two of whom had a liver-related death (both had HCC). Of the 576 
persons who did not meet the criteria for immune active disease, 49 (8.5%) died, and six had 
a liver-related death. Two had HCC, one had bile duct carcinoma, and three had end stage 
liver disease; none had an HBV DNA level above 2,000 IU/ml.
HBsAg levels were performed from stored sera obtained at the time of or within 6 months 
before or after liver biopsy. When stratifying by HBsAg titer <1,000 IU/ml or ≥ 1,000 
IU/ml, no significant differences were found in HAI or fibrosis scores. The HBsAg GMT 
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was not significantly different for those with HAI liver biopsy score of ≥9 vs. < 9 (205 vs. 
525 IU/ml; p=0.449) or Ishak fibrosis scores of ≥2 vs. < 2 (249 vs. 726IU/ml; p=0.154).
Discussion
Our study examined a population-based cohort of persons who were HBeAg-negative and 
were followed prospectively for 8 years to determine the proportion who met the NIH 
criteria for immune active HBV; namely at least one elevated ALT level and one HBV DNA 
level of 2,000 IU/ml or greater.(10) This is the largest population-based prospective study of 
HBeAg-negative persons to date using serial HBV DNA and ALT levels that looked for 
immune active hepatitis. The cohort also included persons infected by five different HBV 
genotypes. We discovered several observations that greatly enhance our understanding of 
the natural history of HBeAg-negative HBV infection. We found that immune active HBV 
infection was significantly more common among men than among women and less likely 
among persons infected with HBV genotype D2 or D3 than those infected with genotypes, 
A2, B6, C2 or F1. While we found an inverse association with BMI and active liver disease; 
this association disappeared after adjusting for gender. Thus we were unable to show any 
association between BMI and severity of liver disease in our cohort. We also observed that 
patients with immune active hepatitis who had levels of aminotransferase levels above both 
twice and ten times the upper limit of normal were more likely to have been infected with 
HBV genotype C. HBV genotype C was found to be associated with a prolonged period of 
HBeAg positivity in this cohort from a previous study and a greater risk of developing 
cirrhosis or HCC than genotype B in prospective outcome studies conducted in Asia where 
this genotype is commonly found.(14-16). We also found that persons in the immune active 
phase with either ALT levels twice the ULN or HBV DNA levels above 20,000 IU/ml were 
more likely to have more advanced liver disease on biopsy.
The majority of persons with chronic HBV infection eventually become negative for 
HBeAg. However the proportion of those who have active liver disease after loss of HBeAg 
or who develop it over time is unknown, though has been estimated to be between 20% to 
40%.(17) In addition, the proportion of HBeAg negative persons who have active liver 
disease varies by HBV genotype and thus will likely vary in different geographic locales, 
depending on the dominant HBV genotypes present.(15) Furthermore, among patients in the 
HBV immune active phase, the factors associated with the presence of moderate to severe 
disease on examination of hepatic pathology that fulfill the criteria for antiviral treatment is 
unknown. Again, this is because population-based studies of HBV with longitudinal clinical 
and laboratory data collection are few. This population-based cohort represents five of the 
eight known HBV genotypes found worldwide and, for those reasons, these findings are 
likely to apply to populations where one or more of these five genotypes is found, including 
most of central and southeast Asia, Europe, the Arctic, the Pacific Islands, North Africa, the 
United States and parts of South America.(15) In this study, we found that levels of both 
HBV DNA and ALT fluctuated widely in HBV infected individuals who were HBeAg-
negative. Thus, relying on a single measurement of these levels in infected persons could be 
misleading. Cross sectional clinic-based studies have reported that approximately one 
quarter of persons with HBV DNA levels of between 2,000 and 20,000 IU/ml can have 
moderate or severe hepatitis on liver biopsy.(18-20) Some experts have recommended that 
McMahon et al. Page 7













persons with an HBV DNA above 2,000 IU/mL and any elevation of ALT should be treated 
with antiviral therapy without the need for a liver biopsy.(21) This study identifies which 
patients in the immune active phase are more likely to have mild disease on liver biopsy and 
which have the highest probability of having moderate or severe liver inflammation or 
fibrosis. We found that those persons who had one or more elevation of HBV DNA of 2,000 
IU/ml or greater but had no determinations above 20,000 IU/ml [the criteria for treatment 
under the current Practice Guidelines from the American Association for the Study of Liver 
Diseases (AASLD)]had only an 11% probability of having moderate or severe liver fibrosis 
on biopsy.(7) Thus treating persons with an elevated ALT and HBV DNA above 2,000 but 
below 20,000 IU/ml without a liver biopsy could result in the use of expensive antiviral 
agents in many persons for whom treatment is not currently recommended in evidenced-
based guidelines established by National and International Liver Societies.(7, 22, 23) In 
contrast, those persons who had one HBV DNA level above 20,000 IU/ml during the 8-year 
follow-up period and/or one ALT level of above twice the upper limit of normal were more 
likely to have moderate to severe inflammation and/or moderate or severe fibrosis on liver 
biopsy and could benefit from antiviral therapy. A previous study supports our findings, for 
which no patients whose HBV DNA level remained between 2,000 and 20,000 IU/ml had 
more than mild liver inflammation or a fibrosis score of > 1 compared to most whose level 
exceeded 20,000 IU/ml. (24)
In those with immune active hepatitis, we found no relationship between the GMT of 
HBsAg levels at the time of biopsy in those with mild vs. moderate to severe liver disease. It 
would be helpful if HBsAg levels could predict the severity of liver disease and thus 
decrease the need for liver biopsy. A larger study should be conducted to confirm that our 
findings are accurate. In a study from Italy, HBsAg and HBV DNA levels were shown to be 
helpful in predicting whether persons in the inactive phase will remain in this phase over a 
3-year follow-up period. (24)
The REVEAL study, a large population-based study looking at adverse clinical outcomes of 
HBV infection, has shown that persons had a significantly high risk of developing HCC if 
they had an HBV DNA level of > 104 copies (2,000 IU/ml) at enrollment and an HBV DNA 
level of >105 copies (20,000 IU/ml) at the end of the study 11 years later, but HBV DNA 
levels in between these time periods were not reported. Though our cohort was on average 
more than a decade younger (mid 30s) at the start of the 8-year follow-up, than were patients 
in the REVEAL cohort (mid 40s), our study findings would likely support those of the 
REVEAL study in that our participants whose HBV DNA levels reached 20,000 IU/ml had a 
greater risk of an adverse outcome or more severe liver disease on biopsy, which could 
subsequently lead to a greater risk of cirrhosis or HCC. We now exclusively prescribe 
tenofovir or entecavir for all therapy-naïve patients who need antiviral treatment and have 
switched those who develop antiviral resistance who were treated earlier with lamivudine or 
adefovir, to the more potent agents.
The three patients who died of endstage liver disease (ESLD) during the study period did not 
meet the HBV DNA criteria for immune active HBV. However, these three patients had a 
history of heavy alcohol use (>50g / day) which has been indicated as a significant factor in 
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ESLD. (22) However further longitudinal follow up is needed to determine the effects of 
antiviral therapy in this cohort.
Our study has some limitations. First, we performed liver biopsy in about one quarter of 
persons who fit the NIH criteria with immune active hepatitis. There are several reasons why 
more persons did not have liver biopsies. Primarily, most of our patients live in remote 
communities that are not connected to the road system and air transportation to Anchorage is 
required for a biopsy. Travel from these remote areas can be over 1000 miles, and is difficult 
and expensive. Thus, not all patients that we recommend for liver biopsy are able to travel 
and have this procedure performed. Eight persons who had ALT levels above twice the ULN 
and HBV DNA levels above 20,000 were empirically put on antiviral therapy without a liver 
biopsy since they met the criteria for treatment and were unable or unwilling to come to 
Anchorage for a liver biopsy. Two other patients were elderly (above age 80) and three 
patients lived in assisted living because of severe physical or mental disabilities. In these 
individuals the decision of whether to treat was made without a liver biopsy. A second 
limitation is that we did not systematically determine the cause of the elevated ALT levels in 
all patients. Thus, some persons with HBV DNA levels above 2,000 may have had non-
hepatitis B related causes that contributed to their elevated ALT levels such as alcohol use or 
non-alcoholic fatty liver disease. Third, since this cohort represents a much younger mean 
age compared to other hepatitis B cohorts, conclusions about the prevalence of moderate to 
severe disease may not be directly comparable and could change as the cohort ages. Finally, 
this cohort consists entirely of Alaska Native persons, over 80% of whom are of Yupik 
Eskimo. It is possible that specific characteristics of this population may exist that would 
make our findings less translatable to other populations. However, thus far, studies have not 
carefully examined ethnic and racial differences in HBV disease outcome, despite numerous 
studies across the world in diverse populations.(17)
In conclusion, to our knowledge, this is the first large population-based prospective cohort 
study that examined the prevalence of immune active disease among HBeAg-negative 
persons. This study cohort represents five of the eight HBV genotypes found worldwide, 
three of which, HBV genotypes C, A2 and D, account for a substantial proportion of the 
global HBV infection burden. We found that approximately one quarter of persons with 
HBeAg-negative chronic HBV infection were in the immune active phase at some time 
during the 8-year follow-up period. Furthermore we found that approximately 90% of 
patients whose HBV DNA levels never reached 20,000 IU/ml had only mild disease on 
biopsy. Our study, along with the prospective cohort study on patients with genotype D (24), 
suggests that clinicians should consider a liver biopsy to stage the degree of pathologic 
severity rather than empirically starting treatment in HBV infected patients with elevated 
ALT levels and an HBV level of between 2,000 and 20,000 IU/ml. Since only a minority of 
these patients meet the AASLD histological criteria for treatment, exposure to possible 
lifelong antiviral therapy may not be justifiable, given the high cost and attendant risk for 
drug resistance.
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